Target intelligence / Profile preview

Aspartic protease 1 from Necator americanus (Na-APR-1)

Target
Na-APR-1
Molecular classification
Enzyme, Aspartic protease, Endopeptidase, Aspartic acid endopeptidase, Clan AA, Family A1, Pepsin-like proteases
01

Overview

Aspartic protease 1 (Na-APR-1) from Necator americanus is a digestive enzyme (aspartic endopeptidase) localized in the gut of the human hookworm. It is responsible for initiating the hemoglobin degradation cascade, a critical step in the worm’s ability to feed on blood and establish infection in the host intestine[1][3][5]. Na-APR-1’s essential role in parasite survival and pathogenesis has led to its development as a leading antigen candidate for hookworm vaccines. When used as a vaccine antigen (often the catalytically inactive Na-APR-1(M74)), it elicits neutralizing antibodies that block the enzyme's activity, potentially interrupting infection and reducing parasite burden in laboratory models and early clinical trials[1][3][7]. Na-APR-1 is not known to be a drug target for small-molecule therapy, but vaccine development is ongoing due to its highly specific biological role and accessibility on the parasite surface[3][5]. If further structuring is needed, the protein is classified as an aspartic acid endopeptidase in Clan AA, Family A1 (pepsin-like proteases) and is critical for the parasite's ability to digest host blood proteins[1][5].

Other names
Aspartic protease-1Na-APR-1Necator americanus hemoglobinaseHookworm hemoglobinase
02

Mechanism of action

Neutralizing antibodies inhibit enzymatic/hemoglobinase activity, blocking blood feeding and impairing worm survival and egg production[1][3].

03

Biological functions

Hemoglobin digestionNutrient acquisition for the parasiteInitiation of proteolytic cascade in parasitism
04

Disease associations

Infection (hookworm disease, specifically caused by Necator americanus)
05

Safety considerations

No major safety issues reported in early-phase clinical trials with recombinant Na-APR-1-based vaccines; main challenges are related to protein expression and yield[3][5].
06

Interacting drugs

None approved for direct inhibition; candidate vaccines in development use catalytically inactive Na-APR-1 as an antigen[3][5].
07

Biomarkers

Anti-Na-APR-1 IgG levels (vaccine response indicator)[3]

Beyond the preview

Go deeper on Aspartic protease 1 from Necator americanus (Na-APR-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspartic protease 1 from Necator americanus (Na-APR-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call